December 2007

Cover Story
Everyone knows about the perverse incentive of fee-for-service medicine, but that hasn’t had much effect on its use

John Carroll

Profits should increase over the next two years for plans that stay the course, but politics and rising premiums may affect long-term results

Martin Sipkoff

The United Kingdom is proving hospitable to UnitedHealth Group and Aetna, and there is business to be had elsewhere in Europe and on other continents

Tom Reinke

There are not many traditional medications in the pipeline, and those that are in development probably won’t make waves

Ed Silverman

Plans prod hospitals to do a better job of addressing problems that kill nearly 100,000 Americans a year

Lola Butcher

Editor's Memo

John Marcille

Legislation & Regulation
The Empire State’s approach to physician ratings quickly gains health plan support and consideration as a national answer

John Carroll

Medication Management
Programs that include a pharmacology benefit reap rewards for the health plan and the member. So why isn’t there 100 percent buy-in?

Martin Sipkoff

Tomorrow’s Medicine
Evithrom may minimize some of the antibody production associated with bovine proteins, but the possibility of human viral infection exists

Thomas Morrow, MD

Health Plan Design
Many new programs offered by insurers bet that individuals, not employers, will one day be making the major decisions

Lola Butcher